SG Americas Securities
PVLA

SG Americas Securities’s Palvella Therapeutics PVLA Stock Holding History

SG Americas Securities’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Buy
3,098
+626
+25% +$76K ﹤0.01% 2349
2026
Q1 		$308K Sell
2,472
-217
-8% -$22.6K ﹤0.01% 2446
2025
Q4 		$281K Buy
+2,689
New +$229K ﹤0.01% 2785
2022
Q1 		– Sell
-230
Closed -$70K – 3529
2021
Q4 		$70K Buy
+230
New +$73.7K ﹤0.01% 3155
2020
Q3 		– Sell
-337
Closed -$84K – 3554
2020
Q2 		$84K Buy
337
+129
+62% +$30.2K ﹤0.01% 3433
2020
Q1 		$38K Buy
+208
New +$52.4K ﹤0.01% 3219
2019
Q1 		– Sell
-170
Closed -$36K – 3678
2018
Q4 		$36K Buy
+170
New +$52.7K ﹤0.01% 2868

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SG Americas Securities's PVLA Position: Q2 2026 in Review

SG Americas Securities increased its Palvella Therapeutics (PVLA) stake by 25% in Q2 2026, buying an estimated $76K and bringing the position to 3,098 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #2349.

SG Americas Securities first reported a position in PVLA in Q4 2018 and has held it in 7 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • SG Americas Securities held 3,098 shares of Palvella Therapeutics worth $473K as of Q2 2026.
  • SG Americas Securities bought 626 Palvella Therapeutics shares in Q2 2026, an estimated $76K.
  • Palvella Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2349 holding.
  • SG Americas Securities first reported a position in Palvella Therapeutics in Q4 2018 and has held it in 7 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.